Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 4 Recurrence 1 Medulloblastoma 1 Gliosarcoma 1 Glioma 1 Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 13 Temozolomide 11 Specimen Handling 8 X-Rays 7 Biopsy 7 Nuclear Medicine Department, Hospital 6 Radiation 5 Phantoms, Imaging 5 erdafitinib 4 ulixertinib 3 trametinib 3 larotrectinib 3 dabrafenib 3 Radiotherapy 3 tipifarnib 2 selpercatinib 2 palbociclib 2 olaparib 2 ivosidenib 2 ensartinib 2 binimetinib 2 D2C7-(scdsFv)-PE38KDEL 2 vorasidenib 1 veliparib 1 trastuzumab deruxtecan 1 trastuzumab biosimilar HLX02 1 temsirolimus 1 tazemetostat 1 selinexor 1 sapanisertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Glioma × Lomustine × 30 days × Clear all

NCT07629089 2026-06-05

VALIENT

University of Pittsburgh

Phase 1 Not yet recruiting

Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡